Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 6 to \< 36 months of age on the day of first study vaccination (study product administration).~* Born at full term of pregnancy (≥37 weeks) and/or with a birth weight ≥2.5 kg. Note: This inclusion criterion only applies to participants 6 to \<12 months of age on the day of the first study visit.~* Informed consent form has been signed and dated by the parent(s) or guardian(s).~* Participant and parent/guardian are able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria:~* Participation at the time of study enrollment (or in the 30 days preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.~* Receipt of any vaccine in the 30 days preceding the first trial vaccination, or planned receipt of any vaccine before Visit 2 for participants receiving 1 dose of influenza vaccine or Visit 3 for participants receiving 2 doses of influenza vaccine.~* Previous vaccination against influenza (in the 2016-2017 season) with either the trial vaccine or another vaccine.~* Receipt of immune globulins, blood, or blood-derived products in the past 3 months.~* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).~* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances.~* Thrombocytopenia, which may be a contraindication for intramuscular vaccination, at the discretion of the Investigator.~* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination.~* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.~* Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.~* Moderate or severe acute illness/infection (according to Investigator judgment) on the day of planned vaccination or febrile illness (temperature ≥100.4 degrees Fahrenheit \[38.0 degrees Celsius\]). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.~* Identified as a natural or adopted child of either the Investigator or an employee with direct involvement in the proposed study.~* History of serious adverse reactions to any influenza vaccine.~* Personal history of Guillain-Barré syndrome.~* Any condition that in the opinion of the Investigator would pose a health risk to the participant if enrolled or could interfere with the evaluation of the vaccine.~* Personal history of clinically significant developmental delay (at the discretion of the Investigator), neurologic disorder, or seizure disorder.~* Known seropositivity for human immunodeficiency virus, hepatitis B, or hepatitis C.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- Fluzone Quadrivalent Vaccine, 0.25-mL (Type: ACTIVE_COMPARATOR): Participants received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.25-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
- Fluzone Quadrivalent Vaccine, 0.5-mL (Type: EXPERIMENTAL): Participants received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.5-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).